Want to see VERA full AI Analyst Report?
VERA Stock Chart & Stats
$42.30
-$0.18(-0.43%)
At close: 4:00 PM EST
$42.30
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$19.07 - $56.05
Previous CloseN/A
Volume142.65K
Average Volume (3M)1.90M
Market Cap
$3.05B
Enterprise Value$2.47B
Total Cash (Recent Filing)$596.76M
Total Debt (Recent Filing)$75.03M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 06, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume3,036,202
30 Day Avg. Volume1,896,540
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.03K
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$82.38Price Target Upside94.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.35
Revenue Forecast (FY)$30.42M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval: TRUTAKNAAccelerated FDA approval converts atacicept from a pure development asset into a commercial product, materially de-risking regulatory timing. This enables initial revenue generation, commercialization planning, and payer engagement that can sustain long-term product adoption in a defined patient population.
Clearer Path To Full ApprovalFDA alignment on an earlier eGFR analysis shortens time uncertainty to potential full approval, improving planning for label expansion and commercial scale-up. A clearly defined regulatory path reduces binary risk and supports sustained investment in marketing and broader clinical adoption.
Relatively Strong Balance SheetLow leverage and ~ $500M of equity give Vera flexibility to fund launch and near-term operations without immediate refinancing. This reduces the probability of urgent dilutive capital raises and supports multi-quarter commercialization and regulatory activities through internal resources.
Bears Say
Pre-revenue, Widening LossesDespite approval, the company has a history of no product revenue and rapidly expanding losses. If commercial uptake, pricing, or reimbursement lag expectations, the firm could remain loss-making for extended periods, limiting reinvestment and pressuring capital structure over months.
High And Rising Cash BurnLarge negative operating cash flow and accelerating FCF burn create ongoing financing needs during launch and broader development. Persistent high burn increases dilution risk or forces partnerships/licensing that could constrain strategic autonomy and long-term margin outcomes.
Severe Value Erosion (negative ROE)Strongly negative ROE and declining equity reflect sustained value erosion from operating losses. This undermines long-term shareholder capital preservation, raises questions about capital allocation effectiveness, and can limit investor appetite for future funding rounds.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $19.07 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $3.05B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 27 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.328 by -$0.362.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.58.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 71,782,906 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.328. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.38 (94.76% Upside)
$82.38 (94.76% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 342.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.4%
Last 30 Days ▲ 26.0%
Last 30 Days ▲ 26.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.34%
12-Months-Change
Fundamentals
Return on Equity
-74.86%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA Stock 12 Month Forecast
Average Price Target
$82.38
▲(94.76% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
8.94% Insiders
16.99% Mutual Funds
0.20% Other Institutional Investors
54.28% Public Companies and
Individual Investors